Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy
The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicincontaining chemotherapy.Seventy-nine patients with PMBCL received CHOP chemotherapy with (n =39) or withoutrituximab (n =40), and 60 patients received additional radiotherapy.Patients treated with rituximab, cyclophosphamiide, doxorubicin, vincristine and prednisone (R-CHOP)had signifietly superior survival rates.The 5-year overallsurvival(OS)and progression-free survival (PFS) rates were 83.7% and 76.7% for R-CHOP, compared with 48.3% (p =0.011) and 44.2%(P =0.012) for CHOP, respectively.Similarly, the5-year PFS rates for early stage patients were 93.8% and 84.6% with R-CHOP and 52.0% (p =0.002) and 46.6% (p =0.003) with CHOP, respectively.Patients treated with chemotherapy and radiotherapy had better survival and local control (LC) rates compared with chemotherapy alone.The 5-year OS, PFS and LC rates for early stage patients were 73.6%, 69.9% and92.6% for chemotherapy and radiotherapy,and 50.8% (p=0.076), 36.9% (p=0.008) and 56.4% (p<0.001) for chemotherapy alone, respectively.Early stage patients treated withR-CHOP and radiotherapy had 5-year OS, PFS and LC rates of 96.4%, 85.9% and93.1 %.R-CHOP plus consolidation radiotherapy was associated with excellent survival and LC rates.
Primary mediastinal large B-cell lymphoma chemotherapy radiotherapy rituximab prognosis
Li-Ming Xu Ye-Xiong Li Hui Fang Wei-Hu Wang Jing Jin Shu-Lian Wang Yue-Ping Liu Yong-Wen Song Hua Ren Li-Qiang Zhou
Department of Radiation Oncology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medica Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peki
国内会议
北京
英文
224-230
2014-01-11（万方平台首次上网日期，不代表论文的发表时间）